The overall ex vivo data exemplified with sera of patients with AD implies that, given a potent IgE neutralizer for treatment of IgE-sensitive allergic diseases, it remains a high-hurdle task to bring down the high serum-free IgE (and so allergen-specific IgE) close to a baseline, single-digit level if the steady, high IgE supply from neosynthesis could not be kept under effective control with measures in addition to simple neutralization of IgE. The gene discussed is IGHE; the disease is allergic disease.